ALZHEIMER'S 7.10.24
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease?utm_medium=email&utm_source=govdelivery
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761248s000lbl.pdf
https://www.aduhelm.com/
https://www.sciencedirect.com/topics/neuroscience/tacrine#:~:text=In%20the%20early%201950s%2C%20tacrine,mild%20to%20moderate%20Alzheimer's%20disease.
https://pink.citeline.com/PS018979/WARNER-LAMBERT-ON-COGNEX-FURTHER-CLINICAL-TRIALS-NOT-REQUIRED
https://www.rexultihcp.com/aad/efficacy?utm_source=google&utm_medium=cpc&utm_term=rexulti_agitation&utm_content=gs_rexulti_general_broad&utm_campaign=gs_branded_general-a&=
https://investor.lilly.com/news-releases/news-release-details/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early

ARIA
https://www.nejm.org/doi/full/10.1056/NEJMoa2212948
https://www.nejm.org/doi/full/10.1056/NEJMoa2100708
https://www.alzforum.org/news/conference-coverage/aducanumab-will-appropriate-use-recommendations-speed-uptake#Galore
https://jamanetwork.com/journals/jamaneurology/fullarticle/2786606



Did not use, but may be interesting
https://www.biospace.com/article/five-alzheimer-s-data-readouts-to-watch-for-in-2024/
https://investors.alector.com/news-releases/news-release-details/alector-announces-completion-enrollment-invoke-2-phase-2
